JP2007527919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007527919A5 JP2007527919A5 JP2007502996A JP2007502996A JP2007527919A5 JP 2007527919 A5 JP2007527919 A5 JP 2007527919A5 JP 2007502996 A JP2007502996 A JP 2007502996A JP 2007502996 A JP2007502996 A JP 2007502996A JP 2007527919 A5 JP2007527919 A5 JP 2007527919A5
- Authority
- JP
- Japan
- Prior art keywords
- substituents
- optionally substituted
- cycloalkyl
- independently
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 33
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 108090000312 Calcium Channels Proteins 0.000 claims 7
- 102000003922 Calcium Channels Human genes 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- -1 1,2-methylenedioxy Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 101150047856 Cav2 gene Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 229920001774 Perfluoroether Polymers 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 claims 1
- 102100025342 Voltage-dependent N-type calcium channel subunit alpha-1B Human genes 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55160604P | 2004-03-08 | 2004-03-08 | |
| US57919304P | 2004-06-10 | 2004-06-10 | |
| PCT/US2005/007920 WO2005087750A1 (en) | 2004-03-08 | 2005-03-07 | Ion channel modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007527919A JP2007527919A (ja) | 2007-10-04 |
| JP2007527919A5 true JP2007527919A5 (https=) | 2008-04-24 |
Family
ID=34975510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007502996A Pending JP2007527919A (ja) | 2004-03-08 | 2005-03-07 | イオンチャンネルモジュレーター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070203194A1 (https=) |
| EP (1) | EP1723123A4 (https=) |
| JP (1) | JP2007527919A (https=) |
| AU (1) | AU2005222402A1 (https=) |
| BR (1) | BRPI0508537A (https=) |
| CA (1) | CA2558224A1 (https=) |
| WO (1) | WO2005087750A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2560954A1 (en) * | 2004-03-26 | 2005-10-20 | Amphora Discovery Corporation | Certain triazole-based compounds, compositions, and uses thereof |
| EP1817295B1 (en) * | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2392328A1 (en) * | 2005-05-09 | 2011-12-07 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 Function |
| CA2653327A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| EP2038262B1 (en) * | 2006-05-25 | 2014-11-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2007267843B2 (en) * | 2006-05-25 | 2011-10-13 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| ME01294B (me) | 2007-11-27 | 2013-06-20 | Ardea Biosciences Inc | Nova jedinjenja i kompozicije i metode upotrebe |
| US8242154B2 (en) | 2008-09-04 | 2012-08-14 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| AR075255A1 (es) * | 2009-02-12 | 2011-03-16 | Exelixis Inc | Derivados diazolicos y/o triazolicos agonistas de receptores tgr5 acoplado a proteina g, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad, diabetes y otros trastornos metabolicos. |
| EP2432468A2 (en) | 2009-05-20 | 2012-03-28 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
| EP2432774A4 (en) * | 2009-05-20 | 2013-01-02 | Ardea Biosciences Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES |
| CN105254557A (zh) * | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| CN102781922A (zh) | 2009-12-11 | 2012-11-14 | 埃克塞利希斯股份有限公司 | Tgr5激动剂 |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| CN105394046B (zh) | 2010-10-25 | 2019-03-01 | 范德比尔特大学 | 用于抑制昆虫宿主感觉的组合物 |
| RU2013128448A (ru) | 2010-12-08 | 2015-01-20 | Осло Юниверсити Хоспитал Хф | Производные триазола в качестве ингибиторов сигнального пути wnt |
| US9578881B2 (en) * | 2011-05-06 | 2017-02-28 | Vanderbilt University | Compositions for inhibition of insect sensing |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| WO2013142346A1 (en) * | 2012-03-23 | 2013-09-26 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| ITMI20120786A1 (it) * | 2012-05-09 | 2013-11-10 | Fond Italiana Sclerosi M Ultipla Fism Onlu | Modulatori del recettore gpr17 |
| KR20150042271A (ko) * | 2012-08-16 | 2015-04-20 | 얀센 파마슈티카 엔.브이. | N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸 |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| CA2950357A1 (en) * | 2014-06-12 | 2015-12-17 | Universite De Lille 2 Droit Et Sante | Imidazol- or 1,2,4-triazol-derivatives and their use |
| EP3273779A4 (en) | 2015-03-25 | 2018-09-05 | Vanderbilt University | Binary compositions as disruptors of orco-mediated odorant sensing |
| US11932610B1 (en) * | 2023-10-17 | 2024-03-19 | King Faisal University | 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoic acid as an antimicrobial compound |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2805756A1 (de) * | 1978-02-10 | 1979-08-16 | Bayer Ag | N-azolylalkyl-aniline sowie verfahren zu ihrer herstellung |
| US4243408A (en) * | 1978-05-11 | 1981-01-06 | Chevron Research Company | Herbicidal N-triazolylmethyl-substituted alpha-haloacetanilide |
| DE2930452A1 (de) * | 1979-07-26 | 1981-02-26 | Bayer Ag | N,n'-bis-(halogenacyl)-diaza-cycloalkane zum schutz von kulturpflanzen vor schaedigungen durch herbizide |
| US5260450A (en) * | 1987-01-27 | 1993-11-09 | Merrell Dow Pharmaceuticals Inc. | 3-aryl-5-alkylthio-4H-1,2,4-triazoles |
| SK16242002A3 (sk) * | 2000-05-19 | 2003-04-01 | Merck Patent Gmbh | Derivát triazolu a farmaceutický prostriedok, ktorý ho obsahuje |
| WO2004030611A2 (en) * | 2002-08-23 | 2004-04-15 | Ribapharm Inc. | Non-nucleoside reverse transcriptase inhibitors |
| US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| WO2004089367A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| US20070196395A1 (en) * | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| WO2005087747A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| EP1723120A4 (en) * | 2004-03-08 | 2007-09-26 | Wyeth Corp | MODULATORS OF THE ION CHANNEL FUNCTION |
| JP2007527920A (ja) * | 2004-03-08 | 2007-10-04 | ワイス | イオンチャンネルモジュレーター |
| AU2005221683A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| EP1722783A4 (en) * | 2004-03-08 | 2009-08-12 | Wyeth Corp | MODULATORS OF THE ION CHANNEL FUNCTION |
| WO2005086836A2 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
| US20070191448A1 (en) * | 2004-03-08 | 2007-08-16 | Robert Zelle | Ion channel modulators |
| US20080139560A1 (en) * | 2004-03-08 | 2008-06-12 | Scion Pharmaceuticals, Inc. | Ion Channel Modulators |
| AU2005221128A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
-
2005
- 2005-03-07 EP EP05725226A patent/EP1723123A4/en not_active Withdrawn
- 2005-03-07 BR BRPI0508537-3A patent/BRPI0508537A/pt not_active IP Right Cessation
- 2005-03-07 CA CA002558224A patent/CA2558224A1/en not_active Abandoned
- 2005-03-07 US US10/592,270 patent/US20070203194A1/en not_active Abandoned
- 2005-03-07 JP JP2007502996A patent/JP2007527919A/ja active Pending
- 2005-03-07 AU AU2005222402A patent/AU2005222402A1/en not_active Abandoned
- 2005-03-07 WO PCT/US2005/007920 patent/WO2005087750A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007527919A5 (https=) | ||
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| JP2019094345A5 (https=) | ||
| JP2020517707A5 (https=) | ||
| JP2006143737A5 (https=) | ||
| JP2023529354A5 (https=) | ||
| JP2004517087A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| MX2010013058A (es) | Derivado de benceno o tiofeno y su uso como inhibidor de proteina 1 de adhesion vascular. | |
| JP2009541220A5 (https=) | ||
| JP2011520896A5 (https=) | ||
| EA027780B1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
| JP2022543155A5 (https=) | ||
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| JPWO2023195529A5 (https=) | ||
| CN107709301B (zh) | 吡唑衍生物或其药理学上可接受的盐 | |
| JP2013540114A5 (https=) | ||
| JP2014518853A5 (https=) | ||
| WO2012152983A1 (en) | Phenyl- sulfonyl derivatives as mediators of trpa1 receptor activity for the treatment of pain | |
| WO2008044656A1 (fr) | Dérivé d'imidazolidinone | |
| JP2005526696A5 (https=) | ||
| JP2016525104A5 (https=) | ||
| JP2010530002A5 (https=) | ||
| JP2010506919A5 (https=) | ||
| JP2008543972A5 (https=) |